Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma

Susan E. Krown(Memorial Sloan Kettering Cancer Center), Dirk P. Dittmer(University of North Carolina at Chapel Hill), Kelong Han(University of Pittsburgh), Jeannette Y. Lee(University of Arkansas at Little Rock), Raman Venkataramanan(University of Pittsburgh), Bruce J. Dezube(Xilio Therapeutics (United States)), Erin Reid(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Debasmita Roy(Bristol-Myers Squibb (United States)), Ethel Cesarman(Cornell University)
JAIDS Journal of Acquired Immune Deficiency Syndromes
November 8, 2011
10.1097/qai.0b013e31823e7884
Cited by 66

Related Papers

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
|Journal of Clinical Oncology|1989|483
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
|JAMA Oncology|2019|446